Bulletin from Annual General Meeting in Boule Diagnostics AB on May 7, 2020

The Annual General Meeting 2020 (the ”AGM”) decided to adopt the balance sheet, income statement, consolidated income statement and consolidated balance sheet for 2019. Furthermore, it was decided that no dividend will be distributed for the financial year 2019 and that the profit shall be carried forward. 

The AGM also decided to discharge the board members and the CEO from liability for 2019.

The AGM approved the nominating committee’s proposal that the board shall consist of five board members without deputies.

The AGM decided that the remuneration to the chairman of the board shall amount to SEK 470,000 (470,000 for 2019) and that the remuneration to the other board members shall be SEK 235,000 (235,000 for 2019) each. The entirety of the board is expected to fulfill the duties of the audit and remuneration committees, and no additional remuneration is proposed for committee work. The total remuneration to the board is hence amounted to SEK 1,410,000 (1,410,000 for 2019).

The AGM also decided that the remuneration to the auditor as previous will be on specified current account approved by the board.

The AGM decided that the board until the end of the next Annual General Meeting will consist of the members Peter Ehrenheim, Jon Risfelt, Thomas Eklund, Karin Dahllöf and Charlotta Falvin through re-election. Peter Ehrenheim was re-elected chairman of the board.

Öhrlings PriceWaterhouseCoopers AB was re-elected as the company’s auditor, with Leonard Daun as auditor in charge, until the end of the Annual General Meeting of 2021.

The AGM approved the proposed principles and instructions for the nomination committee.

The AGM approved the board’s proposed remuneration guidelines for senior management.

The AGM approved the board’s proposal to be authorized to increase share capital through the issue of new shares, options and/or convertibles.             

The AGM approved the board’s proposal to be authorized to make decisions on the acquisition and/or transferal of own shares.

The AGM approved the board’s proposal for the incentive program 2020/2023.

Complete proposals regarding the AGM’s decisions are available in Swedish on Boule’s website http://www.boule.com.

For further information, please contact:
Peter Ehrenheim, Chairman of the Board, Boule Diagnostics AB, phone +46 (0)706-67 57 11
Christina Rubenhag, Acting CEO and CFO, Boule Diagnostics AB, phone +46 (0)705-46 72 22

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com

The information was submitted for publication, through the agency of the contact person set out above, at 20.15 CET on May 7, 2020.


  • Subscribe to our news